Alpha 2.0
Login Register
» Articles » PMID: 34956236

SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination

Overview
Journal Front Immunol
Specialty Allergy & Immunology
Date 2021 Dec 27
PMID 34956236
Citations 19
Authors
Yudi T Pinilla
Constanze Heinzel
Lena-Fabienne Caminada
Douglas Consolaro
Meral Esen
Peter G Kremsner
Jana Held
Andrea Kreidenweiss
Rolf Fendel
Affiliations
Soon will be listed here.
Abstract

SARS-CoV-2 antibodies in saliva serve as first line of defense against the virus. They are present in the mucosa, more precisely in saliva, after a recovered infection and also following vaccination. We report here the antibody persistence in plasma and in saliva up to 15 months after mild COVID-19. The IgG antibody response was measured every two months in 72 participants using an established and validated in-house ELISA assay. In addition, the virus inhibitory activity of plasma antibodies was assessed in a surrogate virus neutralization test before and after vaccination. SARS-CoV-2-specific antibody concentrations remained stable in plasma and saliva and the response was strongly boosted after one dose COVID-19 vaccination.

Citing Articles

Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA).

Wang M, Kamali-Moghaddam M, Lof L, Cortabarria Fernandez M, Diaz Codina R, Sterky F Sci Rep. 2024; 14(1):21655.

PMID: 39289450 PMC: 11408710. DOI: 10.1038/s41598-024-72453-5.

Salivary immune responses after COVID-19 vaccination.

Nguyen K, Relja B, Epperson M, Park S, Thornburg N, Costantini V PLoS One. 2024; 19(9):e0307936.

PMID: 39226256 PMC: 11371244. DOI: 10.1371/journal.pone.0307936.

Immunoglobulin A response to SARS-CoV-2-N-protein potentially persists in oral fluids of patients with periodontitis six months after mRNA vaccine administration.

Bachtiar E, Soeroso Y, Haerani N, Ismah N, Adiati E, Bachtiar B J Dent Sci. 2024; 19(1):652-655.

PMID: 38303837 PMC: 10829667. DOI: 10.1016/j.jds.2023.08.019.

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.

Abela I, Schwarzmuller M, Ulyte A, Radtke T, Haile S, Ammann P mBio. 2024; 15(2):e0272223.

PMID: 38270455 PMC: 10865973. DOI: 10.1128/mbio.02722-23.

Mucosal response of inactivated and recombinant COVID-19 vaccines in Congolese individuals.

Mouzinga F, Heinzel C, Lissom A, Kreidenweiss A, Batchi-Bouyou A, Mbama Ntabi J Immun Inflamm Dis. 2023; 11(12):e1116.

PMID: 38156395 PMC: 10751728. DOI: 10.1002/iid3.1116.

References
1.
Pinilla Y, Friessinger E, Griesbaum J, Berner L, Heinzel C, Elsner K . Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). JMIR Res Protoc. 2021; 10(10):e27739. PMC: 8510152. DOI: 10.2196/27739. View
2.
Heinzel C, Pinilla Y, Elsner K, Friessinger E, Mordmuller B, Kremsner P . Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children. Front Immunol. 2021; 12:753435. PMC: 8531807. DOI: 10.3389/fimmu.2021.753435. View
3.
Pilgrim M, Kasman L, Grewal J, Bruorton M, Werner P, London L . A focused salivary gland infection with attenuated MCMV: an animal model with prevention of pathology associated with systemic MCMV infection. Exp Mol Pathol. 2007; 82(3):269-79. PMC: 3506192. DOI: 10.1016/j.yexmp.2006.12.010. View
4.
Dan J, Mateus J, Kato Y, Hastie K, Yu E, Faliti C . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). PMC: 7919858. DOI: 10.1126/science.abf4063. View
5.
Corbett K, Nason M, Flach B, Gagne M, OConnell S, Johnston T . Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021; 373(6561):eabj0299. PMC: 8449013. DOI: 10.1126/science.abj0299. View